Frontier Biotech's novel long-acting, all-injectable anti-HIV two-drug combination received FDA’s Fast Track designation for treatment of multidrug-resistant HIV-1 infection

Nanjing, China, Nov 7th, 2019 - Frontier Biotechnologies, Inc. (Frontier Biotech) announced that US Food and Drug Administration (USFDA) has granted the Fast Track designation (FTD) to its all-injectable anti-HIV two-drug combination of 3BNC117 and Aikening® for the treatment of multidrug-resis...

2019-11-07 11:15:06

details>

Frontier and Thermo Fisher Sign Strategic Manufacturing Partnership to Accelerate the Commercialization of a Novel Broad-spectrum HIV Neutralizing Antibody

NanjingSep. 26th, 2019 Frontier Biotechnologies (“Frontier Biotech”), a biopharmaceutical company headquartered in China, focusing on innovative drug development for anti-HIV treatment and pain management, and Thermo Fisher Scientific, the world leader in serving science, announced that they have en...

2019-09-29 16:26:53

details>

Frontier Biotech's novel long-acting, all-injectable anti-HIV two-drug combo IND allowed by the US FDA

August 21, 2018 Nanjing, ChinaFrontier Biotech announced today its IND of novel long-acting, all-injectable anti-HIV two drug combo (albuvirtide for injection, ABT and 3BNC117) was allowed by the US FDA on August 14th 2018, and the company will start a phase II clinical trial of the combo therapy in...

2018-08-21 11:00:35

details>

Frontier Biotech Sponsored The “HIV Broad Spectrum Neutralizing Antibodies and Functional Cure” Forum at Tsinghua University

The HIV Forum on "NAbs and Functional Cure" was successfully held by Tsinghua University and Frontier Biotech on Nov 28, 2017 in Beijing. Coming with the 30th World AIDS Day, this event was focused on the latest research of broad neutralizing antibodies (bNAbs) and long-acting drug regimen...

2017-12-20 10:58:36

details>

Press Releases

Frontier Biotech's novel long-acting, all-injectable anti-HIV two-drug combination received FDA’s Fast Track designation for treatment of multidrug-resistant HIV-1 infection

Frontier and Thermo Fisher Sign Strategic Manufacturing Partnership to Accelerate the Commercialization of a Novel Broad-spectrum HIV Neutralizing Antibody

Frontier Biotech's novel long-acting, all-injectable anti-HIV two-drug combo IND allowed by the US FDA

Frontier Biotech Sponsored The “HIV Broad Spectrum Neutralizing Antibodies and Functional Cure” Forum at Tsinghua University

This site is for informational purposes only
and is intended for Healthcare Professionals.

Are you a Healthcare Professional?

Press Releases

Frontier Biotech's novel long-acting, all-injectable anti-HIV two-drug combination received FDA’s Fast Track designation for treatment of multidrug-resistant HIV-1 infection

Frontier and Thermo Fisher Sign Strategic Manufacturing Partnership to Accelerate the Commercialization of a Novel Broad-spectrum HIV Neutralizing Antibody

Frontier Biotech's novel long-acting, all-injectable anti-HIV two-drug combo IND allowed by the US FDA

Frontier Biotech Sponsored The “HIV Broad Spectrum Neutralizing Antibodies and Functional Cure” Forum at Tsinghua University

This site is for informational purposes only and is intended for Healthcare Professionals.

Are you a Healthcare Professional?

This site is for informational purposes only
and is intended for Healthcare Professionals.